CAMP4 Therapeutics receives $100 million in Series B financing

21 July 2022

CAMP4 Therapeutics, a biotech promising to harness the power of RNA to restore healthy protein expression, has announced the close of a $100 milliion Series B financing round, led by Enavate Sciences.

CAMP4’s approach uniquely targets regulatory RNAs (regRNAs), which it describes as being part of the “dark side of the genome,” the 98% of our genome that does not encode proteins. Through breakthroughs in molecular biology, it is now known that regRNAs control the expression of nearby protein-encoding genes.

"Testament to the promise and vast potential of our transformative regulatory RNA platform and the impact it could have for patients with genetic diseases"The financing, which was led by Patient Square Capital portfolio company Enavate Sciences, will be used to develop CAMP4's regRNA programs and accelerate the expansion of its regRNA Actuating Platform.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK